IPHYF News Alert Innate Pharma (IPHYF) 9.7000 10/01/2014 20:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Innate Pharma (IPHYF) 9.7000 $IPHYF

INNATE PHARMA APPOINTS PIERRE DODION AS CHIEF MEDICAL OFFICER AND MEMBER OF THE EXECUTIVE COMMITTEE
GlobeNewswire - Tue Sep 16, 11:40AM CDT
-- Marcel Rozencweig becomes President of Innate Pharma Inc., based in the US

Innate Pharma SA concludes target enrollment of 150 Acute Myeloid Leukemia patients in EffiKIR trial
M2 - Fri Jul 25, 4:59AM CDT
Biopharmaceutical company Innate Pharma SA (Euronext Paris: FR0010331421) revealed on Thursday that it has completed target enrollment in the EffiKIR trial with 150 Acute Myeloid Leukemia (AML) patients randomised.

INNATE PHARMA : Completion of target enrollment in the phase II EffiKIR trial
GlobeNewswire - Thu Jul 24, 12:36AM CDT
-- Data on primary efficacy endpoint Leukemia-Free Survival expected end of 2015

Innate Pharma SA begins Phase I trial with lirilumab and nivolumab in selected solid tumors under cohort expansion
M2 - Mon Mar 31, 4:36AM CDT
Biopharmaceutical company Innate Pharma SA (Euronext Paris: FR0010331421) reported on Monday that it has started the cohort expansion portion of the Phase I clinical trial testing the combination of the two investigational checkpoint inhibitors lirilumab and nivolumab in selected solid tumors.

INNATE PHARMA : Start of cohort expansion of Phase I trial with lirilumab and nivolumab in selected solid tumors
GlobeNewswire - Mon Mar 31, 12:50AM CDT
Start of cohort expansion of Phase I clinical trial testing the combination of lirilumab and nivolumab in selected solid tumors

INNATE PHARMA : announces first DSMB review of ongoing EffiKIR Phase II trial with lirilumab
GlobeNewswire - Tue Sep 17, 1:34AM CDT
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the Data and Safety Monitoring Board ("DSMB" completed its first assessment of the EffiKIR study and unanimously recommended continuation of the trial without modification.

Cutaneous T-Cell Lymphoma - Latest Pipeline Review Report
M2 - Fri Jul 12, 6:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q8vtbk/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2012" report to their offering. 'Cutaneous T-Cell Lymphoma - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma. Scope - A snapshot of the global therapeutic scenario for Cutaneous T-Cell Lymphoma. - A review of the Cutaneous T-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipel

Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013 Report
M2 - Wed Jun 19, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jbrmql/cutaneous_tcell) has announced the addition of the "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013" report to their offering. "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013", provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Cutaneous T-Cell Lymphoma. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Cutaneous T-Cell Lymphoma pipeline depth and focus of Indication th

Sezary Syndrome - Pipeline Review, H1 2013 Contains Latest News and Deals Relating to the Products
M2 - Fri Jun 07, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2npr37/sezary_syndrome) has announced the addition of the "Sezary Syndrome - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Sezary Syndrome - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Sezary Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sezary Syndrome. Sezary Syndrome - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Sezary Syndrom




Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 205

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 404

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 405

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 411

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 299

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 286

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 330

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 196

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 221

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 327

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading

Top 5 Most Recently Viewed Articles

CorMedix Achieves 52-Week High Amidst Business Expansion Strategies

Updated Category News Views 122

CorMedix Stock Reaches New Heights CorMedix Inc. has recently celebrated a milestone by reaching a new 52-week high, with shares hitting $10.15. This significant achievement comes as part of a broader trend of notable expansion and investor confidence in the pharmaceutical and medical device sector. Over the past year, CorMedix's stock has increased by an impressive...

Continue Reading
Norway's Wealth Fund Shifts Ethics Standards Amid Gaza Conflict

Updated Category News Views 148

Norway's Wealth Fund Takes a Stand on Ethical Investments Norway's $1.7 trillion wealth fund is currently navigating a challenging ethical landscape as it considers pulling investments from companies associated with operations in the occupied Palestinian territories. The fund's Council on Ethics has adopted a stricter interpretation of its ethical standards, which could...

Continue Reading
Bonduelle's Monthly Share and Voting Rights Update

Updated Category News Views 120

Overview of Bonduelle's Monthly Share and Voting Rights Update Bonduelle, a prominent player in the food industry, is well-known for its commitment to providing high-quality vegetable products. Headquartered in an innovative facility, their corporate structure includes a significant capital invested which showcases their strong market presence. Latest Information on...

Continue Reading
Innovative Partnership Launches Unique Aging and Cancer Research Institute

Updated Category News Views 193

Innovative Partnership in Cancer Research The Mark Foundation for Cancer Research (MFCR) and the Samuel Waxman Cancer Research Foundation (SWCRF) have entered a groundbreaking collaboration to create the Samuel Waxman Institute for Aging & Cancer. This institute will serve as the first dedicated global center exploring how aging impacts cancer risk throughout a person's...

Continue Reading
Market Overview: Nasdaq Surges as Stocks Show Mixed Trends

Updated Category News Views 201

Market Overview: Nasdaq Shows Strength The U.S. stock markets experienced a mixed performance recently, with the Nasdaq Composite recording a notable gain of over 50 points. This uptick brings attention to sector volatility and specific stock behaviors that investors should closely monitor. Daily Market Trends After the markets opened, the Dow Jones Industrial Average saw...

Continue Reading